Impaired coronary sensitivity to diltiazem in experimental heart failure: Involvement of the cyclooxygenase but not the nitric oxide-synthase pathway

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 2, 1996, Pages 232-239

  Tanguay, Mario ^a   Jasmin, Gaëtan ^a   Blaise, Gilbert ^a   Dumont, Louis ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Coronary flow; Diltiazem; Endothelium; Heart failure; Nitric oxide; Prostaglandin

Indexed keywords

DILTIAZEM; INDOMETACIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DRUG EFFICACY; ENDOTHELIUM; HAMSTER; HEART FAILURE; INOTROPISM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CORONARY VESSELS; CRICETINAE; CYCLOOXYGENASE INHIBITORS; DILTIAZEM; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HEART RATE; HEMODYNAMIC PROCESSES; INDOMETHACIN; MESOCRICETUS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 0029785728     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199608000-00008     Document Type: Article

References (46)

1. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
2. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990:82:1954-61.
3. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. The Adverse Experience Committee, and the Multicenter Diltiazem Postinfarction Research Group: Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
4. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989;80(suppl IV): IV59-67.
5. Porter CB, Walsh RA, Badke FR, O'Rourke RA. Differential effects of diltiazem and nitroprusside on left ventricular function in experimental chronic volume overload. Circulation 1983;68:685-92.
6. Ezzaher A, Bouanani NEH, Su JB, Hittinger L, Crozatier B. Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing hearts. J Pharmacol Exp Ther 1991;257:466-71.
7. Drexler H, Depenbusch JW, Truog AG, Zelis R, Flaim SF. Effects of diltiazem on cardiac function and regional blood flow at rest and during exercise in a conscious rat prepara tion of chronic heart failure (myocardial infarction). Circulation 1985:71:1262-70.
8. Schwinger RH, Böhm M, Erdmann E. Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. J Cardiovasc Pharmacol 1990:15:892-9.
9. Véniant M, Clozel JP, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991;17:277-84.
10. Stewart DJ, Cernacek P, Costello K, Rouleau J-L. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;85:510-7.
11. Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993;88:55-61.
12. Lüscher TF, Noll G. Endothelium-dependent vasomotion in aging, hypertension, and heart failure. Circulation 1993;87 (suppl VII):97-103.
13. Jayakody RL, Kappagoda CT, Senaratne MPJ, Sreeharan N. Absence of effect of calcium antagonists on endothelium-dependent relaxation in rabbit aorta. Br J Pharmacol 1987; 91:155-64.
14. Williams JS, Baik YH, Koch WJ, Schwartz A. A possible role for the endothelium in porcine coronary smooth muscle responses to dihydropyridine calcium antagonists. J Pharmacol Exp Ther 1987;241:379-86.
15. 2+ antagonists. J Cardiovasc Pharmacol 1988;12(suppl 6):S21-8.
16. Vilaine JP, Biondi ML, Villeneuve N, Feletou M, Peglion J-L, Vanhoutte PM. The calcium channel antagonist S 11568 causes endothelium-dependent relaxation in canine arteries. Eur J Pharmacol 1991;197:41-8.
17. 2+ antagonist RO 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol 1994;23:869-76.
18. Weiss MB, Ellis K, Sciacca RR, Johnson LL, Schmidt DH, Cannon PJ. Myocardial blood flow in congestive and hypertrophic cardiomyopathy. Circulation 1976;54:484-94.
19. Vatner SF. Reduced subendocardial myocardial perfusion as one mechanism for congestive heart failure. Am J Cardiol 1988:62:94E-8E.
20. Tanguay M, Lepage G. Blaise G, Garceau D, Dumont L. Resistance of the failing dystrophic hamster heart to the cardioprotective effects of diltiazem and clentiazem: evidence of coronary vascular dysfunctions. Can J Physiol Pharmacol 1994:73:1108-17.
21. Jasmin G, Proschek L. Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. I. Progression of heart and skeletal muscle lesion in the UM-X7.1 line. Muscle Nerve 1982;5:20-5.
22. Canadian Council on Animal Care. Guide to the care and use of experimental animals, vol. 1, 2nd ed. Ottawa: Canadian Council on Animal Care, 1993.
23. Smith REA, Palmer RMJ, Bucknall CA, Moncada S. Role of nitric oxide synthesis in the regulation of coronary vascular tone in the isolated perfused rabbit heart. Cardiovasc Res 1992;26:508-12.
24. Yang BC, Nichols WW, Mehta JL. Cardiac effects of acetylcholine in rat hearts: role of endothelium-derived relaxing factor and prostaglandins. Am J Physiol 1993;264:H1388-93.
25. Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. New York: Springer-Verlag, 1987.
26. i transients in the cardiomyopathic hamster heart. Circ Res 1991;68:45-51.
27. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-16.
28. Sole MJ, Kamble AB, Hussain MN. A possible change in the rate-limiting step for cardiac norepinephrine synthesis in the cardiomyopathic Syrian hamster. Circ Res 1977;41:814-7.
29. Sonnenblick EH, Fein F, Capasso JM, Factor SM. Micro-vascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy, Am J Cardiol 1985;55:179B-84B.
30. 2+ stresses. Circ Res 1991;69:123-33.
31. Roberds SI, Ervasti JM, Anderson RD, et al. Disruption of the dystrophin-glycoprotein complex in the cardiomyopathic hamster. J Biol Chem 1993;268:11496-9.
32. Stefenelli T, Wu ST, Parmley WW, Mason DT, Wikman-Coffelt J. Influence of positive inotropic agents on intracellular calcium transients. Part II. Cardiomyopathic hamster hearts. Am Heart J 1989;118:1228-36.
33. Haleen SJ, Weishaar RE, Overhiser RW, et al. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Circ Res 1991;68:1302-12.
34. Hunter EG, Elbrink J. Increased contractility in vascular smooth muscle of dystrophic hamsters. Can J Physiol Pharmacol 1983;61:182-5.
35. Conway RS, Factor SM, Sonnenblick EH, Baez S. Micro-vascular reactivity of the myopathic Syrian hamster cremaster muscle. Cardiovasc Res 1987;21:796-803.
36. Conway RS, Natelson BH, Chen WH, Ting W. Enhanced coronary vasoconstriction in the Syrian myopathic hamster supports the microvascular spasm hypothesis. Cardiovasc Res 1994;28:320-4.
37. Colucci WS, Fifer MA, Lorell BH, Wynne J. Calcium channel blockers in congestive heart failure: theoretic consider ations and clinical experience. Am J Med 1985;78(suppl 2B): 9-17.
38. Finkel MS. Romeo R, Oddis CV, Salama G. Inotropic effects of calcium antagonists in the cardiomyopathic Syrian hamster. J Cardiovasc Pharmacol 1992;19:546-53.
39. Rubanyi GM, Schwartz A, Vanhoutte PM. Stereoselective effect of diltiazem on endothelium-dependent relaxations in canine femoral arteries. J Pharmacol Exp Ther 1988;246: 60-4.
40. 2+-antagonists in canine depolarized coronary arteries. Br J Pharmacol 1989;98:700-6.
41. Levy BI, El Fertak L, Pieddeloup C, Barouki F, Safar ME. Role of endothelium in the mechanical response of the carotid arterial wall to calcium blockade in spontaneously hypertensive and Wistar-Kyoto rats. J Hypertens 1993;11:57-63.
42. Drexler H. Lu W. Endothelial dysfunction of hindquarter resistance vessels in experimental heart failure. Am J Physiol 1992;262:H1640-5.
43. O'Murchu B, Miller VM, Perrella MA. Burnett JC Jr. Increased production of nitric oxide in coronary arteries during congestive heart failure. J Clin Invest 1994;93:165-71.
44. Kubo SH, Rector TS, Bank AJ, et al. Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. Am J Cardiol 1994;74:1133-6.
45. Okumura K, Yamada Y, Kondo J, Hashimoto H, Ito T, Kitoh J. Decreased 1,2-diacylglycerol levels in myopathic hamster hearts during the development of heart failure. J Mol Cell Cardiol 1991;23:409-16.
46. Seeger W. Röhrenbach M. Ernst C, Neuhof H. Differential influence of calcium channel-blockers on prostanoid generation and thromboxane-mediated vasoconstriction in rabbit lungs. J Pharmacol Exp Ther 1987;242:646-53.